FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57622
News▲ Bullish
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
KINDNews
DIRECTION▲ Bullish
SOURCES4
ENTITIES1
STORY SIZE4 RECORDS
FIRST SEEN2026-09-30 14:15 UTC
LAST UPDATE2026-09-30 18:57 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
EloraTZP beat tirzepatide on weight loss and A1C, reinforcing Lilly's obesity and diabetes franchise.
Combo beats tirzepatide on weight and A1C
CATALYST TO WATCH
Phase 3 initiation and regulatory talks
MAIN RISK
Side-effect profile may limit labeling
FULL DISPATCH
Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg Based on results of this 48-week Phase 2b study,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 4 TIMES · FIRST 2026-09-30 14:15 UTC · LAST 2026-09-30 18:57 UTC2026-09-30 14:15 UTCNewsLilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetesCURRENT RECORD
2026-09-30 14:32 UTCNewsAdding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
2026-09-30 14:32 UTCNewsEli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
2026-09-30 18:57 UTCNewsWall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDEli Lilly · LLY
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares LLY
Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data2026-09-30 18:57 UTC
Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data2026-09-30 18:57 UTC
←CORRELATIONshares LLY
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis2026-09-30 12:03 UTC
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis2026-09-30 12:03 UTC
←CORRELATIONshares LLY
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.2026-09-30 14:32 UTC
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.2026-09-30 14:32 UTC
←CORRELATIONshares LLY
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial2026-09-30 14:32 UTC
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial2026-09-30 14:32 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.